Abstract
OBJECTIVES: To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated (FLT3(mut) ) and FLT3-wild-type (FLT3(wt) ) acute myeloid leukemia (AML). METHODS: Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ≥65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R). RESULTS: Charts of 1027 AML patients were included (183 FLT3(mut) 18-64 ND; 136 FLT3(mut) ≥65 ND; 181 FLT3(mut) R/R; 186 FLT3(wt) 18-64 ND; 159 FLT3(wt) ≥65 ND; 182 FLT3(wt) R/R). Substantial heterogeneity was observed in treatment patterns for AML. Among ND patients 18-64, the most common initial treatment was standard-to-intermediate dose cytarabine-based therapies (43.2% for FLT3(mut) and 55.9% for FLT3(wt) ); among ND patients ≥65, the most common initial treatment was hypomethylating agent-based therapies (36.0% and 47.2%). Among R/R patients, the most common initial treatment after R/R was best supportive care only (39.8% and 24.7%). HRU was substantial across cohorts during both event-free and post-event periods. CONCLUSIONS: Treatment patterns of AML were heterogeneous and FLT3(mut) AML was treated more aggressively than FLT3(wt) disease. HRU was substantial for all cohorts, particularly after relapse or treatment failure.